About
Mike Nohaile is the Chief Executive Officer of Prellis Biologics, a Berkeley-area biotech company focused on AI-enabled antibody discovery. Business Wire reported in August 2022 that he joined Prellis after leadership roles at Generate Biomedicines, Amgen, and Novartis. He also appears as a participant in Bluenote's 2024 funding round, indicating some angel-style investing activity, but not enough disclosed financial data to classify him as a capital owner under this schema.
Areas of interest
biotechantibody therapeuticsdrug discoveryartificial intelligencemachine learningimmunologylife sciences